Reuters logo
BRIEF-Genentech Announces Positive Interim Results From Phase 3 Study Evaluating Hemlibra
December 7, 2017 / 6:07 AM / in 6 days

BRIEF-Genentech Announces Positive Interim Results From Phase 3 Study Evaluating Hemlibra

Dec 7 (Reuters) - Genentech:

* GENENTECH-POSITIVE INTERIM RESULTS FROM PHASE III EVALUATING HEMLIBRA DOSED ONCE EVERY FOUR WEEKS IN ADULTS AND ADOLESCENTS WITH HEMOPHILIA A

* GENENTECH SAYS RESULTS ARE CONSISTENT WITH PREVIOUS STUDIES OF HEMLIBRA DOSED ONCE WEEKLY OR EVERY TWO WEEKS Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below